Bioinformatics Analysis Reveals an Association between Autophagy, Prognosis, Tumor Microenvironment, and Immunotherapy in Osteosarcoma

Figure 7

Evaluation of anti-PD-1/PD-L1 immunotherapy based on risk signature. (a) Risk score of patients in the anti-PD-L1 cohort who showed different responses to anti-PD-L1 therapy. (b) The response rate of high-risk score group and low-risk score group to anti-PD-L1 therapy in the anti-PD-L1 cohort. (c) Survival analysis of patients with low-risk score and high-risk score in the IMvigor210 cohort. (d) The survival curve of patients with low-risk score and high-risk score in the IMvigor210 cohort with stage I-II. (e) The Kaplan-Meier curve of stage III-IV patients with different risk score in IMvigor210 cohort. (f) Risk score differences between different ICB treatment groups in the anti-PD1 cohort. (g) The percentage of patients who responded to PD-1 blocking immunotherapy in different risk groups. (h) The Kaplan-Meier curve showed the prognosis of patients in the anti-PD1 cohort classified as high-risk and low-risk groups. The asterisks represent the statistical p value (ns, no statistical difference, , ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)